ReviewCurrent cardiology reports2018
The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
Review in Current cardiology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Metabolic alterations associated with sacubitril/valsartan treatment: a systematic review and meta-analysis.BMC cardiovascular disorders · 2026Pooled it
- The efficacy and safety of sacubitril/valsartan compared with ACEI/ARB in the treatment of heart failure following acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2023Pooled it
- The Effects of Sacubitril/Valsartan Compared to Olmesartan on the Blood Pressure and Glucolipid Metabolism in DM Patients with Primary Hypertension.Cardiovascular drugs and therapy · 2024Trial
- Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Trial
- Bibliometric analysis of sacubitril/valsartan in the management of chronic kidney disease (2013-2025).Renal failure · 2026Review
- Pathophysiology, diagnosis and intervention strategies of nocturnal hypertension.Journal of human hypertension · 2026Review
- Associations of Neprilysin and Its Coding Gene Variation With Hypertension in Chinese Adults.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Angiotensin receptor-neprilysin inhibitors improve the outcome of lung cancer patients with hypertension undergoing immune checkpoint inhibitors treatment.BMC cardiovascular disorders · 2025Article
- Interconnected pathways and emerging therapies in chronic kidney disease and heart failure: A comprehensive review.ESC heart failure · 2025Review
- A Distinctive Metabolomics Pattern Associated with the Administration of Combined Sacubitril/Valsartan to Healthy Subjects: A Kinetic Approach.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Impact of Sitagliptin on Neprilysin and Glycemic Control in Newly Diagnosed Type 2 Diabetes Patients.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Cardiac and kidney outcomes after sacubitril-valsartan therapy: recovery of cardiac function relative to kidney function decline.Kidney research and clinical practice · 2024Article
- Multi-Target In-Silico modeling strategies to discover novel angiotensin converting enzyme and neprilysin dual inhibitors.Scientific reports · 2024Article
- Pseudo-nephropathy and hyper-excretion of urinary C-peptide: an overlooked adverse effect of an angiotensin receptor-neprilysin inhibitor (ARNI).Diabetology international · 2024Article
- The recent advance and prospect of natural source compounds for the treatment of heart failure.Heliyon · 2024Review
- Effect of sacubitril-valsartan on left ventricular remodeling and NT-proBNP in patients with heart failure complicated with hypertension and reduced ejection fraction.American journal of translational research · 2024Article
- A comprehensive review of the literature on CD10: its function, clinical application, and prospects.Frontiers in pharmacology · 2024Review
- Empagliflozin combined with sacubitril/valsartan in hypertensive patients with heart failure: a retrospective study of efficacy and effect on blood pressure variability and cardiac function.American journal of translational research · 2024Article
- Enhancing ventricular remodeling and cardiac function in post-acute myocardial infarction with sacubitril/valsartan.American journal of translational research · 2024Article
- Dapagliflozin-entresto protected kidney from renal hypertension via downregulating cell-stress signaling and upregulating SIRT1/PGC-1α/Mfn2-medicated mitochondrial homeostasis.Experimental biology and medicine (Maywood, N.J.) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewSacubitril/valsartan (LCZ696) is a first-in-class, novel-acting, angiotensin receptor neprilysin inhibitor (ARNI) that provides inhibition of neprilysin and the angiotensin (AT RECENT
findingsA recent mechanistic study PARAMETER demonstrated that sacubitril/valsartan (LCZ696) is superior to angiotensin receptor blocker (ARB) monotherapy for reducing central aortic systolic pressure (primary endpoint) as well as for central aortic pulse pressure (secondary endpoint) and nocturnal BP preferentially. Considering these results, sacubitril/valsartan may be an attractive therapeutic agent to treat the elderly with age-related hypertension phenotypes, such as drug-uncontrolled (resistant) hypertension characterized as systolic (central) hypertension (structural hypertension) and/or nocturnal hypertension (salt-sensitive hypertension). These are the high-risk hypertension phenotypes which are prone to develop heart failure with preserved EF and chronic kidney disease. Sacubitril/valsartan may be effective to suppress the age-related continuum from hypertension to heart failure, and it could be clinically useful not only for secondary prevention, but also as primary prevention of heart failure in uncontrolled elderly hypertensive patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.